The aim of the OriON JA is to make available a mainly qualitative analysis of the national cancer control situation in the Member States, including the state of play of implementation of Europe’s Beating Cancer Plan at national level in a comparable and frequently updated form as well as to make available data and insights on socio-economic inequalities to complement and enhance the analysis for the Cancer Inequalities Registry.

Project description

The OriON Joint Action is proposed for funding in response to the flagship No 9 of the Europe’s Beating Cancer Plan (EBCP), which defines that the EC will establish a Cancer Inequalities Registry to identify trends, disparities and inequalities in cancer prevention and care between and within European Member States (MS) and regions. Through the newly established European Cancer Inequalities Registry, a consolidated view of the national cancer control landscape across the EU and resulting inequalities will assist in targeting investments and interventions at Union, national and regional level to address trends, disparities and inequalities between MS and regions. The expected impact will be a reduction in measurable disparities in cancer prevention and care across the EU.

The OriON JA will have three general objectives (Monitoring of EBCP uptake and implementation in European MS, Piloting of the EBCP Monitoring & Evaluation framework, Maximizing the impact of the EBCP generated knowledge and evidence) and two specific objectives (To support the monitoring and analysis of the implementation of EBCP & To carry out an analysis of the state-of-play of National Cancer Control Programmes with a special focus on the inequalities). Work within the JA will be organized in five WPs, three horizontal and two core WPs (Sustainability and implementation – support to the monitoring and analysis of the implementation of EBCP & Analysis of the developments in NCCPs).

The primary target group of the OriON JA are policy makers from MS and their representatives, and the secondary target group will consist of EU organizations, experts, patient advocates and representatives as well as patients from across Europe. Citizens and patients from all European countries will benefit from the OriON JA because together with the Cancer Inequalities Registry, the JA will contribute to reducing measurable disparities in cancer prevention and care across the EU.